Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  degarelix
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS21, NCT00295750
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS21A, 2006-006913-34, NCT00451958
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS29, 2008-003931-19, NCT00801242
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS30, 2008-005232-33, NCT00833248
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS31, 2008-008604-40, NCT00884273
A Study of Degarelix in Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS37, RISPSA, NCT00928434
A Trial of Degarelix in Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS35, 2008-005276-27, NCT00946920
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS34, EudraCT No: 2008-006827-29, NCT00967018
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS42, NCT01071915
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS42A, NCT01215513
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS43, NCT01220869
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 000006, NCT01744366
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3550-CL-0010, NCT01964170
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and over
Sponsor: Other
Protocol IDs: J1265, NA_00073453, NCT01696877
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS15, NCT00116753
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS18, NCT00468286
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
Phase: Phase II
Type: Treatment
Status: Completed
Age: 55 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS25, 2007-003578-24, NCT00527488
Phase II Study of ASP3550 in Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3550-CL-0003, NCT00568516
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS27, 2008-000585-22, NCT00738673
Study to Find Maintenance Dose for Periodic Administration of ASP3550
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3550-CL-0009, NCT01261572
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000696565, S1014, U10CA032102, SWOG-S1014, NCT01309672
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0378, NCI-2011-01125, NCT01377389
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 000008, NCT01491971
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Phase: No phase specified
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS46, NCT01215526
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS39, NCT01234350
Start Over